Carcinomas epiteliales del ovario de alto y bajo grado: Estado de Arte

Autores:: Hernández, Diana
González, Yezid

Tipo de recurso:: Article of journal

Fecha de publicación:: 2015

Institución:: Fundación Universitaria de Ciencias de la Salud - FUCS

Repositorio:: Repositorio Digital Institucional ReDi

Idioma:: spa

id	FUCS2_001773cc78e74baa5a0cb49e9624857c
oai_identifier_str	oai:repositorio.fucsalud.edu.co:001/2520
network_acronym_str	FUCS2
network_name_str	Repositorio Digital Institucional ReDi
repository_id_str
dc.title.spa.fl_str_mv	Carcinomas epiteliales del ovario de alto y bajo grado: Estado de Arte
dc.title.translated.eng.fl_str_mv	Epithelial carcinomas of the ovary of high and low grade: State of Art
title	Carcinomas epiteliales del ovario de alto y bajo grado: Estado de Arte
spellingShingle	Carcinomas epiteliales del ovario de alto y bajo grado: Estado de Arte carcinoma de ovario tumores tipo I-II BRAF KRAS p-53 Ovarian carcinoma type I-II tumors BRAF KRAS p-53
title_short	Carcinomas epiteliales del ovario de alto y bajo grado: Estado de Arte
title_full	Carcinomas epiteliales del ovario de alto y bajo grado: Estado de Arte
title_fullStr	Carcinomas epiteliales del ovario de alto y bajo grado: Estado de Arte
title_full_unstemmed	Carcinomas epiteliales del ovario de alto y bajo grado: Estado de Arte
title_sort	Carcinomas epiteliales del ovario de alto y bajo grado: Estado de Arte
dc.creator.fl_str_mv	Hernández, Diana González, Yezid
dc.contributor.author.spa.fl_str_mv	Hernández, Diana González, Yezid
dc.subject.spa.fl_str_mv	carcinoma de ovario tumores tipo I-II BRAF KRAS p-53
topic	carcinoma de ovario tumores tipo I-II BRAF KRAS p-53 Ovarian carcinoma type I-II tumors BRAF KRAS p-53
dc.subject.eng.fl_str_mv	Ovarian carcinoma type I-II tumors BRAF KRAS p-53
publishDate	2015
dc.date.accessioned.none.fl_str_mv	2015-06-01 00:00:00 2022-02-21T20:38:20Z
dc.date.issued.none.fl_str_mv	2015-06-01
dc.date.available.none.fl_str_mv	2015-06-01 00:00:00 2022-02-21T20:38:20Z
dc.type.spa.fl_str_mv	Artículo de revista
dc.type.eng.fl_str_mv	Journal article
dc.type.coar.fl_str_mv	http://purl.org/coar/resource_type/c_2df8fbb1
dc.type.coar.spa.fl_str_mv	http://purl.org/coar/resource_type/c_6501
dc.type.driver.spa.fl_str_mv	info:eu-repo/semantics/article
dc.type.version.spa.fl_str_mv	info:eu-repo/semantics/publishedVersion
dc.type.content.spa.fl_str_mv	Text
dc.type.coarversion.spa.fl_str_mv	http://purl.org/coar/version/c_970fb48d4fbd8a85
format	http://purl.org/coar/resource_type/c_6501
status_str	publishedVersion
dc.identifier.doi.none.fl_str_mv	10.31260/RepertMedCir.v24.n2.2015.630
dc.identifier.issn.none.fl_str_mv	0121-7372
dc.identifier.uri.none.fl_str_mv	https://repositorio.fucsalud.edu.co/handle/001/2520
dc.identifier.eissn.none.fl_str_mv	2462-991X
dc.identifier.url.none.fl_str_mv	https://doi.org/10.31260/RepertMedCir.v24.n2.2015.630
identifier_str_mv	10.31260/RepertMedCir.v24.n2.2015.630 0121-7372 2462-991X
url	https://repositorio.fucsalud.edu.co/handle/001/2520 https://doi.org/10.31260/RepertMedCir.v24.n2.2015.630
dc.language.iso.spa.fl_str_mv	spa
language	spa
dc.relation.references.spa.fl_str_mv	Intenational Agency for research On Cancer. Globocan 2012. Estimated incidence, mortality and prevalence worldwide in 2012 [monograph on the Internet]. Lyon, France: Worl Health Organitation; 2012 [cited 2015 Mar 10]. Disponible en: http://globocan.iarc.fr/Pages/fact_sheets_population.aspx. Lim D, Oliva E. Precursors and pathogenesis of ovarian carcinoma. Pathology. 2013; 45(3):229-42. Gong TT, Wu QJ, Vogtmann E, Lin B, Wang YL. Age at menarche and risk of ovarian cancer: a meta-analysis of epidemiological studies. Int J Cancer. 2013; 132(12):2894-900. Faber MT, Kjær SK, Dehlendorff C, Chang-Claude J, Andersen KK, Hogdall E, et al. Cigarette smoking and risk of ovarian cancer: a pooled analysis of 21 case–control studies. Cancer Causes Control. 2013; 24(5):989-1004 Blaustein A, Kurman RJ, Elleson LH, Ronnett BM. Patología del tracto genital femenino de Blaustein. 7th ed. Caracas : Amolca; 2014. Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature. 2011; 474(7353):609-15. Novoa-Vargas A. [Natural history of ovary cancer]. Ginecol Obstet Mex. 2014; 82(9):613-22. Farghaly SA. The role of oral contraceptive pills (OCPs) in chemoprevention of epithelial ovarian cancer in women with mutant BRCA1 and BRCA2 Genes. J Cancer Sci Ther. 2013; 5(8): 1000–124. Kohn EC, Hurteau J. Ovarian cancer : making its own rules-again. Cancer. 2013; 119(3):474-6. Koshiyama M, Matsumura N, Konishi I. Recent concepts of ovarian carcinogenesis: type I and type II. Biomed Res Int. 2014;2014:934261. Jelovac D, Armstrong DK. Recent progress in the diagnosis and treatment of ovarian cancer. CA Cancer J Clin. 2011; 61(3):183-203. Prat J. New insights into ovarian cancer pathology. Ann Oncol. 2012 Sep;23 Suppl 10:x111-7 del Carmen MG, Birrer M, Schorge JO. Clear cell carcinoma of the ovary: a review of the literature. Gynecol Oncol. 2012; 126(3):481-90. Okamoto A, Glasspool RM, Mabuchi S, Matsumura N, Nomura H, Itamochi H, et al. Gynecologic cancer inter group (GCIG) consensus review for clear cell carcinoma of the ovary. Int J Gynecol Cancer. 2014; 24(9 Suppl 3):S20-5. Dabbs DJ. Diagnostic immunohistochemistry. 4th ed. Philadelphia: Saunders; 2014. 960 p. Tsuchiya A, Sakamoto M, Yasuda J, Chuma M, Ohta T, Ohki M, et al. Expression profiling in ovarian clear cell carcinoma: identification of hepatocyte nuclear factor-1 beta as a molecular marker and a possible molecular target for therapy of ovarian clear cell carcinoma. Am J Pathol. 2003; 163(6):2503-12. Okamoto T, Mandai M, Matsumura N, Yamaguchi K, Kondoh H, Amano Y, et al. Hepatocyte nuclear factor-1beta (HNF-1beta) promotes glucose uptake and glycolytic activity in ovarian clear cell carcinoma. Mol Carcinog. 2015 ;54(1):35-49. Maeda D, Shih Ie M. Pathogenesis and the role of ARID1A mutation in endometriosis-related ovarian neoplasms. Adv Anat Pathol. 2013; 20(1):45-52. Kajihara H, Yamada Y, Shigetomi H, Higashiura Y, Kobayashi H. The dichotomy in the histogenesis of endometriosis-associated ovarian cancer: clear celltype versus endometrioid-type adenocarcinoma. Int J Gynecol Pathol. 2012; 31(4):304-12. Shappell HW, Riopel MA, Smith Sehdev AE, Ronnett BM, Kurman RJ. Diagnostic criteria and behavior of ovarian seromucinous (endocervical-type mucinous and mixed cell-type) tumors: atypical proliferative (borderline) tumors, intraepithelial, microinvasive, and invasive carcinomas. Am J Surg Pathol. 2002; 26(12):1529-41. Ledermann JA, Luvero D, Shafer A, O’Connor D, Mangili G, Friedlander M, et al. Gynecologic cancer intergroup (gcig) consensus review for mucinous ovarian carcinoma. Int J Gynecol Cancer. 2014; 24(9 Suppl 3):S14-9. Frumovitz M, Schmeler KM, Malpica A, Sood AK, Gershenson DM. Unmasking the complexities of mucinous ovarian carcinoma. Gynecol Oncol. 2010; 117(3):491–6. Rechsteiner M, Zimmermann AK, Wild PJ, Caduff R, von Teichman A, et al. TP53 mutations are common in all subtypes of epithelial ovarian cancer and occur concomitantly with KRAS mutations in the mucinous type. Exp Mol Pathol. 2013 Oct;95(2):235-41. Gourley C, Farley J, Provencher DM, Pignata S, Mileshkin L, Harter P, et al. Gynecologic cancer intergroup (GCIG) consensus review for ovarian and primary peritoneal low-grade serous carcinomas. Int J Gynecol Cancer. 2014; 24(9 Suppl 3):S9-s13. McCluggage WG. Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis. Pathology. 2011; 43(5):420-32. Boyd J, Luo B, Peri S, Wirchansky B, Hughes L, Forsythe C, et al. Whole exome sequence analysis of serous borderline tumors of the ovary. Gynecol Oncol. 2013; 130(3):560-4. Grisham RN, Iyer G, Garg K, DeLair D, Hyman DM, Zhou Q et al. BRAF Mutation is associated with early stage disease and improved outcome in patients with low-grade serous ovarian cancer. Cancer. 2014; 119(3):548-54. Ingin RJ, Andola SK, Zubair AA. Transitional cell carcinoma of the ovary: case series and review of literature. J Clin Diagn Res. 2014; 8(8):FD07-8. Kurman RJ, Elleson LH, Ronnett BM. Patología del tracto genital femenino de Blaustein. 7a ed. Caracas: Amolca; 2014. Roma AA, Masand RP. Ovarian Brenner tumors and Walthard nests: a histologic and immunohistochemical study. Hum Pathol. 2014; 45(12):2417-22 Kommoss F, Kommoss S, Eichhorn J, Schmidt D. [Transitional cell carcinoma of the ovary. Morphological and clinical features]. Pathologe. 2007; 28(3):209-14. Hannibala CG, Vang R, Junge J, Kjaerbye-Thygesen A, Kurman RJ, Kjaer SK. A Binary histologic grading system for ovarian serous carcinoma is an independent prognostic factor: a population-based study of 4,317 women diagnosed in denmark 1978-2006. Gynecol Oncol. 2012;125(3):655-60. Diniz PM, Carvalho JP, Baracat EC, Carvalho FM. Fallopian tube origin of supposed ovarian high-grade serous carcinomas. Clinics (Sao Paulo). 2011; 66(1):73-6. Piek JM, van Diest PJ, Zweemer RP, Jansen JW, Poort-Keesom RJ, Menko FH, et al. Dysplastic changes in prophylactically removed Fallopian tubes of women predisposed to developing ovarian cancer. J Pathol. 2001; 195(4):451-6. Kurman RJ. Origin and molecular pathogenesis of ovarian high-grade serous carcinoma. Ann Oncol. 2013; 24 Suppl 10:x16-21. Yemelyanova A, Vang R, Kshirsagar M, Lu D, Marks MA, Shih Ie M, et al. Immunohistochemical staining patterns of p53 can serve as a surrogate marker for TP53 mutations in ovarian carcinoma: an immunohistochemical and nucleotide sequencing analysis. Mod Pathol. 2011; 24(9):1248-53. Chene G, Rahimi K, Mes-Masson AM, Provencher D. Surgical implications of the potential new tubal pathway for ovarian carcinogenesis. J Minim Invasive Gynecol. 2013; 20(2):153-9. Chen EY, Mehra K, Mehrad M, Ning G, Miron A, Mutter GL, et al. Secretory cell outgrowth, PAX2 and serous carcinogenesis in the Fallopian tube. J Pathol. 2010; 222(1):110-6. Kuhn E, Kurman RJ, Vang R, Sehdev AS, Han G, Soslow R, et al. TP53 mutations in serous tubal intraepithelial carcinoma and concurrent pelvic high-grade serous carcinoma - evidence supporting the clonal relationship of the two lesions. J Pathol. 2012; 226(3):421-6. Rabban JT, Krasik E, Chen LM, Powell CB, Crawford B, Zaloudek CJ. Multistep level sections to detect occult fallopian tube carcinoma in risk-reducing salpingooophorectomies from women with BRCA mutations: implications for defining an optimal specimen dissection protocol. Am J Surg Pathol. 2009; 33(12):1878-85. Reed NS, Pautier P, Avall-Lundqvist E, Choi CH, du Bois A, Friedlander M, et al. Gynecologic cancer intergroup (GCIG) consensus review for ovarian small cell cancers. Int J Gynecol Cancer. 2014; 24(9 Suppl 3):S30-4. Ki EY, Park JS, Lee KH, Bae SN, Hur SY. Large cell neuroendocrine carcinoma of the ovary: a case report and a brief review of the literature. World J Surg Oncol. 2014; 12(1):314. Ramos P, Karnezis AN, Craig DW, Sekulic A, Russell ML, Hendricks WP, et al. Small cell carcinoma of the ovary, hypercalcemic type, displays frequent inactivating germline and somatic mutations in SMARCA4. Nat Genet. 2014; 46(5):427-9. Berton-Rigaud D, Devouassoux-Shisheboran M, Ledermann JA, Leitao MM, Powell MA, Poveda A, et al. Gynecologic cancer intergroup (GCIG) consensus review for uterine and ovarian carcinosarcoma. Int J Gynecol Cancer. 2014; 24(9 Suppl 3):S55-60. Lamb MR, Gertsen E, Middlemas E. Carcinosarcoma of the ovary: case report and literature review. Tenn Med. 2012; 105(3):41-2. del Carmen MG, Birrer M, Schorge JO. Carcinosarcoma of the ovary: a review of the literature. Gynecol Oncol. 2012; 125(1):271-7. Growdon WB, Roussel BN, Scialabba VL, Foster R, Dias-Santagata D, Iafrate AJ, et al. Tissue-specific signatures of activating PIK3CA and RAS mutations in carcinosarcomas of gynecologic origin. Gynecol Oncol. 2011; 121(1):212-7. Reade CJ, Finlayson S, McAlpine J, Tone AA, Fung-Kee-Fung M, Ferguson SE. Risk-reducing salpingectomy in Canada: a survey of obstetrician-gynaecologists. J Obstet Gynaecol Can. 2013; 35(7):627-34. Yokoyama Y, Mizunuma H. Recurrent epithelial ovarian cancer and hormone therapy. World J Clin Cases. 2013; 1(6):187-90. Schenberg T, Mitchell G. Prophylactic bilateral salpingectomy as a prevention strategy in women at high-Risk of ovarian cancer: a mini-review. Front Oncol. 2014;4:1-4 Kurta ML, Edwards RP, Moysich KB, McDonough K, Bertolet M, Weissfeld JL, et al. Prognosis and conditional disease-free survival among patients with ovarian cancer. J Clin Oncol. 2014; 32(36):4102-12.
dc.relation.bitstream.none.fl_str_mv	https://revistas.fucsalud.edu.co/index.php/repertorio/article/download/630/668
dc.relation.citationedition.spa.fl_str_mv	Núm. 2 , Año 2015 : Abril – Junio
dc.relation.citationendpage.none.fl_str_mv	112
dc.relation.citationissue.spa.fl_str_mv	2
dc.relation.citationstartpage.none.fl_str_mv	105
dc.relation.citationvolume.spa.fl_str_mv	24
dc.relation.ispartofjournal.spa.fl_str_mv	Revista Repertorio de Medicina y Cirugía
dc.rights.spa.fl_str_mv	Fundación Universitaria de Ciencias de la Salud FUCS - 0
dc.rights.accessrights.spa.fl_str_mv	info:eu-repo/semantics/openAccess
dc.rights.uri.spa.fl_str_mv	https://creativecommons.org/licenses/by-nc-sa/4.0/
dc.rights.coar.spa.fl_str_mv	http://purl.org/coar/access_right/c_abf2
rights_invalid_str_mv	Fundación Universitaria de Ciencias de la Salud FUCS - 0 https://creativecommons.org/licenses/by-nc-sa/4.0/ http://purl.org/coar/access_right/c_abf2
eu_rights_str_mv	openAccess
dc.format.mimetype.spa.fl_str_mv	application/pdf
dc.publisher.spa.fl_str_mv	Sociedad de Cirugía de Bogotá, Hospital de San José y Fundación Universitaria de Ciencias de la Salud
dc.source.spa.fl_str_mv	https://revistas.fucsalud.edu.co/index.php/repertorio/article/view/630
institution	Fundación Universitaria de Ciencias de la Salud - FUCS
bitstream.url.fl_str_mv	https://repositorio.fucsalud.edu.co/bitstreams/5093bbe6-67c7-4282-986a-cbea523e5e13/download
bitstream.checksum.fl_str_mv	2f8094559440967c2a67375db831025c
bitstream.checksumAlgorithm.fl_str_mv	MD5
repository.name.fl_str_mv	Repositorio Digital de la Fundación Universitaria de Ciencias de la Salud
repository.mail.fl_str_mv	redi@fucsalud.edu.co
_version_	1814355551068356608
spelling	Hernández, Diana2281287b86e5f6fad54d5236ccf13915González, Yezid000826138033d71a0e53d0b3aaa630e53002015-06-01 00:00:002022-02-21T20:38:20Z2015-06-012015-06-01 00:00:002022-02-21T20:38:20ZSociedad de Cirugía de Bogotá, Hospital de San José y Fundación Universitaria de Ciencias de la SaludFundación Universitaria de Ciencias de la Salud FUCS - 0info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/4.0/http://purl.org/coar/access_right/c_abf2https://revistas.fucsalud.edu.co/index.php/repertorio/article/view/630carcinoma de ovariotumores tipo I-IIBRAFKRASp-53Ovarian carcinomatype I-II tumorsBRAFKRASp-53Carcinomas epiteliales del ovario de alto y bajo grado: Estado de ArteEpithelial carcinomas of the ovary of high and low grade: State of Artapplication/pdfArtículo de revistaJournal articlehttp://purl.org/coar/resource_type/c_6501http://purl.org/coar/resource_type/c_2df8fbb1info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionTexthttp://purl.org/coar/version/c_970fb48d4fbd8a8510.31260/RepertMedCir.v24.n2.2015.6300121-7372https://repositorio.fucsalud.edu.co/handle/001/25202462-991Xhttps://doi.org/10.31260/RepertMedCir.v24.n2.2015.630spaIntenational Agency for research On Cancer. Globocan 2012. Estimated incidence, mortality and prevalence worldwide in 2012 [monograph on the Internet]. Lyon, France: Worl Health Organitation; 2012 [cited 2015 Mar 10]. Disponible en: http://globocan.iarc.fr/Pages/fact_sheets_population.aspx.Lim D, Oliva E. Precursors and pathogenesis of ovarian carcinoma. Pathology. 2013; 45(3):229-42.Gong TT, Wu QJ, Vogtmann E, Lin B, Wang YL. Age at menarche and risk of ovarian cancer: a meta-analysis of epidemiological studies. Int J Cancer. 2013; 132(12):2894-900.Faber MT, Kjær SK, Dehlendorff C, Chang-Claude J, Andersen KK, Hogdall E, et al. Cigarette smoking and risk of ovarian cancer: a pooled analysis of 21 case–control studies. Cancer Causes Control. 2013; 24(5):989-1004Blaustein A, Kurman RJ, Elleson LH, Ronnett BM. Patología del tracto genital femenino de Blaustein. 7th ed. Caracas : Amolca; 2014.Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature. 2011; 474(7353):609-15.Novoa-Vargas A. [Natural history of ovary cancer]. Ginecol Obstet Mex. 2014; 82(9):613-22.Farghaly SA. The role of oral contraceptive pills (OCPs) in chemoprevention of epithelial ovarian cancer in women with mutant BRCA1 and BRCA2 Genes. J Cancer Sci Ther. 2013; 5(8): 1000–124.Kohn EC, Hurteau J. Ovarian cancer : making its own rules-again. Cancer. 2013; 119(3):474-6.Koshiyama M, Matsumura N, Konishi I. Recent concepts of ovarian carcinogenesis: type I and type II. Biomed Res Int. 2014;2014:934261.Jelovac D, Armstrong DK. Recent progress in the diagnosis and treatment of ovarian cancer. CA Cancer J Clin. 2011; 61(3):183-203.Prat J. New insights into ovarian cancer pathology. Ann Oncol. 2012 Sep;23 Suppl 10:x111-7del Carmen MG, Birrer M, Schorge JO. Clear cell carcinoma of the ovary: a review of the literature. Gynecol Oncol. 2012; 126(3):481-90.Okamoto A, Glasspool RM, Mabuchi S, Matsumura N, Nomura H, Itamochi H, et al. Gynecologic cancer inter group (GCIG) consensus review for clear cell carcinoma of the ovary. Int J Gynecol Cancer. 2014; 24(9 Suppl 3):S20-5.Dabbs DJ. Diagnostic immunohistochemistry. 4th ed. Philadelphia: Saunders; 2014. 960 p.Tsuchiya A, Sakamoto M, Yasuda J, Chuma M, Ohta T, Ohki M, et al. Expression profiling in ovarian clear cell carcinoma: identification of hepatocyte nuclear factor-1 beta as a molecular marker and a possible molecular target for therapy of ovarian clear cell carcinoma. Am J Pathol. 2003; 163(6):2503-12.Okamoto T, Mandai M, Matsumura N, Yamaguchi K, Kondoh H, Amano Y, et al. Hepatocyte nuclear factor-1beta (HNF-1beta) promotes glucose uptake and glycolytic activity in ovarian clear cell carcinoma. Mol Carcinog. 2015 ;54(1):35-49.Maeda D, Shih Ie M. Pathogenesis and the role of ARID1A mutation in endometriosis-related ovarian neoplasms. Adv Anat Pathol. 2013; 20(1):45-52.Kajihara H, Yamada Y, Shigetomi H, Higashiura Y, Kobayashi H. The dichotomy in the histogenesis of endometriosis-associated ovarian cancer: clear celltype versus endometrioid-type adenocarcinoma. Int J Gynecol Pathol. 2012; 31(4):304-12.Shappell HW, Riopel MA, Smith Sehdev AE, Ronnett BM, Kurman RJ. Diagnostic criteria and behavior of ovarian seromucinous (endocervical-type mucinous and mixed cell-type) tumors: atypical proliferative (borderline) tumors, intraepithelial, microinvasive, and invasive carcinomas. Am J Surg Pathol. 2002; 26(12):1529-41.Ledermann JA, Luvero D, Shafer A, O’Connor D, Mangili G, Friedlander M, et al. Gynecologic cancer intergroup (gcig) consensus review for mucinous ovarian carcinoma. Int J Gynecol Cancer. 2014; 24(9 Suppl 3):S14-9.Frumovitz M, Schmeler KM, Malpica A, Sood AK, Gershenson DM. Unmasking the complexities of mucinous ovarian carcinoma. Gynecol Oncol. 2010; 117(3):491–6.Rechsteiner M, Zimmermann AK, Wild PJ, Caduff R, von Teichman A, et al. TP53 mutations are common in all subtypes of epithelial ovarian cancer and occur concomitantly with KRAS mutations in the mucinous type. Exp Mol Pathol. 2013 Oct;95(2):235-41.Gourley C, Farley J, Provencher DM, Pignata S, Mileshkin L, Harter P, et al. Gynecologic cancer intergroup (GCIG) consensus review for ovarian and primary peritoneal low-grade serous carcinomas. Int J Gynecol Cancer. 2014; 24(9 Suppl 3):S9-s13.McCluggage WG. Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis. Pathology. 2011; 43(5):420-32.Boyd J, Luo B, Peri S, Wirchansky B, Hughes L, Forsythe C, et al. Whole exome sequence analysis of serous borderline tumors of the ovary. Gynecol Oncol. 2013; 130(3):560-4.Grisham RN, Iyer G, Garg K, DeLair D, Hyman DM, Zhou Q et al. BRAF Mutation is associated with early stage disease and improved outcome in patients with low-grade serous ovarian cancer. Cancer. 2014; 119(3):548-54.Ingin RJ, Andola SK, Zubair AA. Transitional cell carcinoma of the ovary: case series and review of literature. J Clin Diagn Res. 2014; 8(8):FD07-8.Kurman RJ, Elleson LH, Ronnett BM. Patología del tracto genital femenino de Blaustein. 7a ed. Caracas: Amolca; 2014.Roma AA, Masand RP. Ovarian Brenner tumors and Walthard nests: a histologic and immunohistochemical study. Hum Pathol. 2014; 45(12):2417-22Kommoss F, Kommoss S, Eichhorn J, Schmidt D. [Transitional cell carcinoma of the ovary. Morphological and clinical features]. Pathologe. 2007; 28(3):209-14.Hannibala CG, Vang R, Junge J, Kjaerbye-Thygesen A, Kurman RJ, Kjaer SK. A Binary histologic grading system for ovarian serous carcinoma is an independent prognostic factor: a population-based study of 4,317 women diagnosed in denmark 1978-2006. Gynecol Oncol. 2012;125(3):655-60.Diniz PM, Carvalho JP, Baracat EC, Carvalho FM. Fallopian tube origin of supposed ovarian high-grade serous carcinomas. Clinics (Sao Paulo). 2011; 66(1):73-6.Piek JM, van Diest PJ, Zweemer RP, Jansen JW, Poort-Keesom RJ, Menko FH, et al. Dysplastic changes in prophylactically removed Fallopian tubes of women predisposed to developing ovarian cancer. J Pathol. 2001; 195(4):451-6.Kurman RJ. Origin and molecular pathogenesis of ovarian high-grade serous carcinoma. Ann Oncol. 2013; 24 Suppl 10:x16-21.Yemelyanova A, Vang R, Kshirsagar M, Lu D, Marks MA, Shih Ie M, et al. Immunohistochemical staining patterns of p53 can serve as a surrogate marker for TP53 mutations in ovarian carcinoma: an immunohistochemical and nucleotide sequencing analysis. Mod Pathol. 2011; 24(9):1248-53.Chene G, Rahimi K, Mes-Masson AM, Provencher D. Surgical implications of the potential new tubal pathway for ovarian carcinogenesis. J Minim Invasive Gynecol. 2013; 20(2):153-9.Chen EY, Mehra K, Mehrad M, Ning G, Miron A, Mutter GL, et al. Secretory cell outgrowth, PAX2 and serous carcinogenesis in the Fallopian tube. J Pathol. 2010; 222(1):110-6.Kuhn E, Kurman RJ, Vang R, Sehdev AS, Han G, Soslow R, et al. TP53 mutations in serous tubal intraepithelial carcinoma and concurrent pelvic high-grade serous carcinoma - evidence supporting the clonal relationship of the two lesions. J Pathol. 2012; 226(3):421-6.Rabban JT, Krasik E, Chen LM, Powell CB, Crawford B, Zaloudek CJ. Multistep level sections to detect occult fallopian tube carcinoma in risk-reducing salpingooophorectomies from women with BRCA mutations: implications for defining an optimal specimen dissection protocol. Am J Surg Pathol. 2009; 33(12):1878-85.Reed NS, Pautier P, Avall-Lundqvist E, Choi CH, du Bois A, Friedlander M, et al. Gynecologic cancer intergroup (GCIG) consensus review for ovarian small cell cancers. Int J Gynecol Cancer. 2014; 24(9 Suppl 3):S30-4.Ki EY, Park JS, Lee KH, Bae SN, Hur SY. Large cell neuroendocrine carcinoma of the ovary: a case report and a brief review of the literature. World J Surg Oncol. 2014; 12(1):314.Ramos P, Karnezis AN, Craig DW, Sekulic A, Russell ML, Hendricks WP, et al. Small cell carcinoma of the ovary, hypercalcemic type, displays frequent inactivating germline and somatic mutations in SMARCA4. Nat Genet. 2014; 46(5):427-9.Berton-Rigaud D, Devouassoux-Shisheboran M, Ledermann JA, Leitao MM, Powell MA, Poveda A, et al. Gynecologic cancer intergroup (GCIG) consensus review for uterine and ovarian carcinosarcoma. Int J Gynecol Cancer. 2014; 24(9 Suppl 3):S55-60.Lamb MR, Gertsen E, Middlemas E. Carcinosarcoma of the ovary: case report and literature review. Tenn Med. 2012; 105(3):41-2.del Carmen MG, Birrer M, Schorge JO. Carcinosarcoma of the ovary: a review of the literature. Gynecol Oncol. 2012; 125(1):271-7.Growdon WB, Roussel BN, Scialabba VL, Foster R, Dias-Santagata D, Iafrate AJ, et al. Tissue-specific signatures of activating PIK3CA and RAS mutations in carcinosarcomas of gynecologic origin. Gynecol Oncol. 2011; 121(1):212-7.Reade CJ, Finlayson S, McAlpine J, Tone AA, Fung-Kee-Fung M, Ferguson SE. Risk-reducing salpingectomy in Canada: a survey of obstetrician-gynaecologists. J Obstet Gynaecol Can. 2013; 35(7):627-34.Yokoyama Y, Mizunuma H. Recurrent epithelial ovarian cancer and hormone therapy. World J Clin Cases. 2013; 1(6):187-90.Schenberg T, Mitchell G. Prophylactic bilateral salpingectomy as a prevention strategy in women at high-Risk of ovarian cancer: a mini-review. Front Oncol. 2014;4:1-4Kurta ML, Edwards RP, Moysich KB, McDonough K, Bertolet M, Weissfeld JL, et al. Prognosis and conditional disease-free survival among patients with ovarian cancer. J Clin Oncol. 2014; 32(36):4102-12.https://revistas.fucsalud.edu.co/index.php/repertorio/article/download/630/668Núm. 2 , Año 2015 : Abril – Junio112210524Revista Repertorio de Medicina y CirugíaPublicationOREORE.xmltext/xml2516https://repositorio.fucsalud.edu.co/bitstreams/5093bbe6-67c7-4282-986a-cbea523e5e13/download2f8094559440967c2a67375db831025cMD51001/2520oai:repositorio.fucsalud.edu.co:001/25202024-02-02 13:08:47.329https://creativecommons.org/licenses/by-nc-sa/4.0/Fundación Universitaria de Ciencias de la Salud FUCS - 0metadata.onlyhttps://repositorio.fucsalud.edu.coRepositorio Digital de la Fundación Universitaria de Ciencias de la Saludredi@fucsalud.edu.co

Carcinomas epiteliales del ovario de alto y bajo grado: Estado de Arte

Publicaciones similares